Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 5/20 | 0.81 |
| ▸ | HTR2C | P28335 | 14/20 | 0.68 |
| ▸ | HTR2B | P41595 | 12/20 | 0.68 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10350527 | 0.98 | PNMT (0.78) | PNMTHTR2CHTR2BADRA2AADRA2B | |
| SCHEMBL10623977 | 0.95 | PNMT (0.73) | PNMTHTR2CHTR2BADRA2AADRA2B | |
| SCHEMBL17056235 | 0.89 | PNMT (1.00) | PNMTHTR2CHTR2BADRA2AADRA2B | |
| SCHEMBL8112619 | 0.89 | PNMT (0.87) | PNMTHTR2CHTR2BADRA2AADRA2B | |
| SCHEMBL30487466 | 0.89 | PNMT (0.87) | PNMTHTR2CHTR2BADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL11483568 | 0.88 | PNMT (0.97) | PNMTHTR2CHTR2BADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL4788258 | 0.88 | PNMT (0.84) | PNMTHTR2CHTR2BADRA2AADRA2B | |
| SCHEMBL11948273 | 0.82 | PNMT (0.61) | PNMTHTR2CHTR2B | |
| SCHEMBL12828070 | 0.82 | CA12 (0.66) | PNMTHTR2CHTR2B | |
| SCHEMBL4767812 | 0.82 | HTR2C (0.64) | PNMTHTR2CHTR2BADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0229510-B1 | SULFINYL AND SULFONYL SUBSTITUTED-3-BENZAZEPINES | SMITHKLINE BEECHAM CORPORATION (US) | 1990-06-06 | — | — | EP | claimed |
| US-4824839-A | Sulfinyl and sulfonyl substituted 2,3,4,5 tetrahydro-1H-3-benzazepines and their use in treating gastrointestinal motility disorders | SMITHKLINE BECKMAN CORPORATION (US) | 1989-04-25 | — | — | US | claimed |
| WO-1988007858-A1 | SULFINYL AND SULFONYL SUBSTITUTED 3-BENZAZEPINES | SMITHKLINE BECKMAN CORPORATION (US) | 1988-10-20 | — | — | WO | claimed |
| EP-0229510-A1 | Sulfinyl and sulfonyl substituted-3-benzazepines | SMITHKLINE BEECHAM CORPORATION (US) | 1987-07-22 | — | — | EP | claimed |
| EP-1725241-A4 | M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2009-03-25 | — | — | EP | disclosed |
| US-20090042862-A1 | NOVEL COMPOUNDS | BEST DESMOND JOHN | 2009-02-12 | — | — | US | disclosed |
| US-7446103-B2 | Bicyclic benzamide compound as histamine H3 receptor ligand useful in the treatment of neurological diseases | GLAXO GROUP LIMITED (GB) | 2008-11-04 | — | — | US | disclosed |
| US-7429579-B2 | Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents) | SMITHKLINE BEECHAM, PLC (GB) | 2008-09-30 | — | — | US | disclosed |
| EP-1335915-B1 | TETRAHYDROBENZAZEPINE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM PLC (GB) | 2008-01-02 | — | — | EP | disclosed |
| US-20070185088-A1 | M3 muscarinic acetylchoine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070105838-A1 | Bicyclic Benzamide Compoundssa as Histamine H3 Receptor Ligand Useful in the Treatment of Neurological Diseases | GLAXO GROUP LIMITED (GB) | 2007-05-10 | — | — | US | disclosed |
| US-20070027118-A1 | Novel compounds of amino sulfonyl derivatives | AGOURON PHARMACEUTICALS, INC | 2007-02-01 | — | — | US | disclosed |
| WO-2002040471-A2 | TETRAHYDROBENZAZEPINE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-05-23 | — | — | WO | disclosed |
| EP-1119563-A1 | TETRAHYDROBENZAZEPINE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM PLC (GB) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000021951-A1 | TETRAHYDROBENZAZEPINE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM PLC (GB) | 2000-04-20 | — | — | WO | disclosed |
| US-4824839-A | Sulfinyl and sulfonyl substituted 2,3,4,5 tetrahydro-1H-3-benzazepines and their use in treating gastrointestinal motility disorders | SMITHKLINE BECKMAN CORPORATION (US) | 1989-04-25 | — | — | US | disclosed |
| US-4824839-A | Sulfinyl and sulfonyl substituted 2,3,4,5 tetrahydro-1H-3-benzazepines and their use in treating gastrointestinal motility disorders | SMITHKLINE BECKMAN CORPORATION (US) | 1989-04-25 | — | — | US | disclosed |
| WO-1988007858-A1 | SULFINYL AND SULFONYL SUBSTITUTED 3-BENZAZEPINES | SMITHKLINE BECKMAN CORPORATION (US) | 1988-10-20 | — | — | WO | disclosed |
| WO-1988007858-A1 | SULFINYL AND SULFONYL SUBSTITUTED 3-BENZAZEPINES | SMITHKLINE BECKMAN CORPORATION (US) | 1988-10-20 | — | — | WO | disclosed |
| EP-0229510-A1 | Sulfinyl and sulfonyl substituted-3-benzazepines | SMITHKLINE BEECHAM CORPORATION (US) | 1987-07-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105838-A1 | Bicyclic Benzamide Compoundssa as Histamine H3 Receptor Ligand Useful in the Treatment of Neurological Diseases | HRH3, HRH4, HRH1 | PNMT 380/4885HTR2C 39/4885HTR2B 22/4885 |
| US-20090042862-A1 | NOVEL COMPOUNDS | GRIN2C, GRIN2A, GRIN2B | PNMT 98/4885HTR2C 24/4885HTR2B 21/4885 |
| US-20070027118-A1 | Novel compounds of amino sulfonyl derivatives | HSD11B1, HSD11B2, HSD17B11 | PNMT 2750/4885HTR2C 499/4885HTR2B 443/4885 |
| US-20070185088-A1 | M3 muscarinic acetylchoine receptor antagonists | CHRM3, CHRM2, CHRM5 | PNMT 275/4885HTR2C 271/4885HTR2B 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.